Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Loebinger

Showing results (91-100 of 149) with videos related to

Pageof 15
Sort By:
Annals of the American Thoracic Society|April 22, 2022
Multiple-Breath Washout Outcome Measures in Adults with BronchiectasisKatherine O'Neill, Gokul R Lakshmipathy, Curtis Neely, et al.
ERJ Open Research|January 16, 2024
<i>Mycobacterium avium</i> complex pulmonary disease patients with limited treatment optionsStefano Aliberti, Francesco Blasi, Pierre-Régis Burgel, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Characterization of Eosinophilic Bronchiectasis: A European Multicohort StudyAmelia Shoemark, Michal Shteinberg, Anthony De Soyza, et al.
The Lancet. Respiratory Medicine|November 20, 2016
Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort studyMelissa J McDonnell, Stefano Aliberti, Pieter C Goeminne, et al.
The New England Journal of Medicine|April 23, 2025
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in BronchiectasisJames D Chalmers, Pierre-Régis Burgel, Charles L Daley, et al.
Respiratory Medicine|December 6, 2024
Airway total bacterial density, microbiota community composition and relationship with clinical parameters in bronchiectasisZina Alfahl, Gisli G Einarsson, J Stuart Elborn, et al.
Trials|December 21, 2019
A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trialJudy Martina Bradley, Rohan Anand, Brenda O'Neill, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 5, 2013
BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungsGerd Döring, Alessandra Bragonzi, Moira Paroni, et al.
The European Respiratory Journal|November 6, 2025
Consensus on the management of refractory nontuberculous mycobacterial pulmonary diseaseDiana Moreira-Sousa, Beatriz Martins, Ana Aguiar, et al.
Pulmonology|February 24, 2026
Management of nontuberculous mycobacterial Pulmonary disease refractory to guideline-based therapy: A systematic reviewDiana Moreira-Sousa, Beatriz Martins, Ana Aguiar, et al.
Pageof 15

Showing results (91-100 of 149) with videos related to

Sort By:
Pageof 15
Annals of the American Thoracic Society|April 22, 2022
Multiple-Breath Washout Outcome Measures in Adults with BronchiectasisKatherine O'Neill, Gokul R Lakshmipathy, Curtis Neely, et al.
ERJ Open Research|January 16, 2024
<i>Mycobacterium avium</i> complex pulmonary disease patients with limited treatment optionsStefano Aliberti, Francesco Blasi, Pierre-Régis Burgel, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Characterization of Eosinophilic Bronchiectasis: A European Multicohort StudyAmelia Shoemark, Michal Shteinberg, Anthony De Soyza, et al.
The Lancet. Respiratory Medicine|November 20, 2016
Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort studyMelissa J McDonnell, Stefano Aliberti, Pieter C Goeminne, et al.
The New England Journal of Medicine|April 23, 2025
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in BronchiectasisJames D Chalmers, Pierre-Régis Burgel, Charles L Daley, et al.
Respiratory Medicine|December 6, 2024
Airway total bacterial density, microbiota community composition and relationship with clinical parameters in bronchiectasisZina Alfahl, Gisli G Einarsson, J Stuart Elborn, et al.
Trials|December 21, 2019
A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trialJudy Martina Bradley, Rohan Anand, Brenda O'Neill, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 5, 2013
BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungsGerd Döring, Alessandra Bragonzi, Moira Paroni, et al.
The European Respiratory Journal|November 6, 2025
Consensus on the management of refractory nontuberculous mycobacterial pulmonary diseaseDiana Moreira-Sousa, Beatriz Martins, Ana Aguiar, et al.
Pulmonology|February 24, 2026
Management of nontuberculous mycobacterial Pulmonary disease refractory to guideline-based therapy: A systematic reviewDiana Moreira-Sousa, Beatriz Martins, Ana Aguiar, et al.
Pageof 15